Research Paper

O’Neill, P., Mestre-Ferrandiz, J., Puig-Peiro, R. and Sussex, J.

Research Paper
January 2014

The Pharmaceutical Price Regulation Scheme (PPRS) 2014 Heads of Agreement, announced on 6 November 2013, outlines the terms of the five-year deal between the pharmaceuctical industry and the government in the UK. For the first time, the PPRS caps future growth in the NHS's branded medicines bill, between 2014 and 2018.

Karlsberg Schaffer, S., Sussex, J., Devlin, N. and Walker, A.

Research Paper
December 2013

This research examines the use of QALY thresholds in NHS Scotland in 2012-13 for health services that were "at the margin", i.e. those for which investment or disinvestment was planned or occurred.

The study was based on information from three sources: public information from the Scottish Parliament's examination of the NHS Boards' expenditure plans, interviews with the Finance Directors of Scotland's territorial NHS Boards, and a literature review.

Dakin, H., Devlin, N., Feng, Y., Rice, N., O'Neill, P. and Parkin, D.

Research Paper
November 2013

In this Research Paper, the authors explore which factors have most influenced NICE decisions from 1999 through the end of 2011. The research has two objectives: identifying the influence of cost-effectiveness and other factors on NICE decisions, and investigating whether NICE’s decision making has changed over time.

Cubi-Molla, P., de Vries, J and Devlin, N.

Research Paper
July 2013

Significantly increases of wealth and health in the Western world over the past 50 years do not appear to have produced an equivalent increase in societal happiness, at least not using traditional measures. As a result, policy makers now are looking more closely at alternative ways of measuring the welfare of society, including measures of subjective well-being.

Garau, M., Shah, K., Sharma, P. and Towse, A.

Research Paper
May 2013

Is the Link Between Health and Wealth Considered in Decision Making? Results from a Qualitative Study

Sussex, J., Rollet, P., Garau, M., Schmitt, C., Kent, A. and Hutchings, A.

Research Paper
May 2013

The purpose of this research is to identify the attributes to include in a value framework for orphan medicinal products (OMPs), determine their relative importance using a multi-criteria decision analysis (MCDA) process, and test whether an MCDA approach can support decision making in practice.

O’Neill, P., Mestre-Ferrandiz, J., Puig-Peiro, R. and Sussex, J.

Research Paper
April 2013

Medicines account for less than 10% of total NHS expenditure in the UK. Because spending on medicines is easy to separate out, however, this sector continues to come under particular scrutiny in efforts to manage costs. Forecasting spending on medicines can be useful in planning NHS resource allocation. Simple extrapolations of past trends in medicines expenditure, however, are insufficient because they cannot account for shifts in the mix of medicines available on the market or the appearance of generics.

Karlsberg Schaffer, S.

Research Paper
February 2013

Forecasters predict that the population of people aged 65+ in the UK will double by 2050, constituting a quarter of the total population. This will seriously challenge the NHS and the social care system. The ageing population is expensive: average NHS spending on 65+ households is nearly double that on households under 65 years of age. Formal care provided by the state, however, is not the only resource on which the elderly rely. England alone has nearly six million informal carers.

Shah, K. and Devlin, N.

Research Paper
December 2012

The UK Government is proposing to include "burden of illness" criteria in its scheme for value based pricing of branded medicines, potentially according higher rewards to medicines that treat more burdensome diseases. The 2010 Consultation Document includes a definition of burden of illness that incorporates both severity (length or quality of life) and "unmet need" (whether and what treatment exists). Little empirical evidence is available, however, on societal attitudes towards these definitions.

Shah, K., Tsuchiya, A., Risa Hole, A. and Wailoo, A.

Research Paper
December 2012

In 2009, the UK’s National Institute for Health and Clinical Excellence (NICE) issued supplementary advice that its Appraisal Committees are to consider when assessing treatments that extend life at the end of life.  This includes an option for approving such treatments for use in the NHS if certain criteria are met, even if base case cost-effectiveness estimates exceed the range usually considered acceptable.

Pages

Subscribe to RSS - Research Paper